Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform
CARY, N.C., July 6 /PRNewswire-FirstCall/ — Cornerstone Therapeutics Inc. (Nasdaq: CRTX) (“Cornerstone”), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 …
Read more on redOrbit